IDH1 and acute myeloid leukemia: For the IDH1 inhibitor ivosidenib the combination with azacitidine has been shown to be superior to azacitidine monotherapy, inducing CR in 47% vs. 15% in newly diagnosed AML patients, which led to approval by the FDA in May 2022 [63].